Vident Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,144
| Closed | -$217K | – | 49 |
|
|
2023
Q2 | $217K | Buy |
+1,144
| New | +$217K | 0.01% | 1025 |
|
|
2022
Q2 | – | Sell |
-12,161
| Closed | -$1.98M | – | 1274 |
|
|
2022
Q1 | $1.98M | Buy |
12,161
+5,136
| +73% | +$838K | 0.05% | 457 |
|
|
2021
Q4 | $1.19M | Sell |
7,025
-4,255
| -38% | -$722K | 0.03% | 643 |
|
|
2021
Q3 | $2.13M | Buy |
11,280
+889
| +9% | +$168K | 0.06% | 372 |
|
|
2021
Q2 | $1.76M | Sell |
10,391
-1,206
| -10% | -$204K | 0.05% | 460 |
|
|
2021
Q1 | $1.64M | Buy |
11,597
+651
| +6% | +$91.9K | 0.06% | 467 |
|
|
2020
Q4 | $1.42M | Buy |
10,946
+873
| +9% | +$113K | 0.06% | 427 |
|
|
2020
Q3 | $1.47M | Sell |
10,073
-289
| -3% | -$42.1K | 0.07% | 374 |
|
|
2020
Q2 | $1.53M | Buy |
10,362
+7,603
| +276% | +$1.13M | 0.08% | 302 |
|
|
2020
Q1 | $300K | Buy |
2,759
+366
| +15% | +$39.8K | 0.02% | 684 |
|
|
2019
Q4 | $276K | Sell |
2,393
-1,756
| -42% | -$203K | 0.02% | 649 |
|
|
2019
Q3 | $334K | Sell |
4,149
-1,321
| -24% | -$106K | 0.03% | 422 |
|
|
2019
Q2 | $397K | Sell |
5,470
-3,422
| -38% | -$248K | 0.03% | 396 |
|
|
2019
Q1 | $831K | Buy |
8,892
+1,528
| +21% | +$143K | 0.04% | 450 |
|
|
2018
Q4 | $537K | Sell |
7,364
-170
| -2% | -$12.4K | 0.03% | 564 |
|
|
2018
Q3 | $659K | Sell |
7,534
-89
| -1% | -$7.79K | 0.03% | 595 |
|
|
2018
Q2 | $751K | Buy |
7,623
+3,157
| +71% | +$311K | 0.03% | 510 |
|
|
2018
Q1 | $429K | Buy |
4,466
+2,400
| +116% | +$231K | 0.02% | 683 |
|
|
2017
Q4 | $262K | Buy |
+2,066
| New | +$262K | 0.01% | 722 |
|